Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
Identifieur interne : 000327 ( Istex/Curation ); précédent : 000326; suivant : 000328Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
Auteurs : Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-03-15.
English descriptors
- KwdEn :
Abstract
The purpose of this study to compare the long‐term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early‐start group) or placebo for 6 months followed by rasagiline (delayed‐start group) in the TEMPO study. Subjects who chose to participate in an open‐label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5‐year follow‐up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early‐start versus delayed‐start rasagiline group. Although the interaction between treatment and time was significant, values for the early‐start group were better than the delayed‐start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early‐start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22402
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000327
Links to Exploration step
ISTEX:5B1103AD18D631B83CB2914DC8D246159F83891DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="1"><mods:affiliation>Parkinsons's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinsons's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, California</wicri:regionArea></affiliation></author><author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea></affiliation></author><author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea></affiliation></author><author><name sortKey="Fitzer Ttas, Cheryl J" sort="Fitzer Ttas, Cheryl J" uniqKey="Fitzer Ttas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name><affiliation wicri:level="1"><mods:affiliation>Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel</mods:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Teva Pharmaceutical Industries Ltd, Petach Tikva</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5B1103AD18D631B83CB2914DC8D246159F83891D</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22402</idno><idno type="url">https://api.istex.fr/document/5B1103AD18D631B83CB2914DC8D246159F83891D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000327</idno><idno type="wicri:Area/Istex/Curation">000327</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="1"><mods:affiliation>Parkinsons's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinsons's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, California</wicri:regionArea></affiliation></author><author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania</wicri:regionArea></affiliation></author><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea></affiliation></author><author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea></affiliation></author><author><name sortKey="Fitzer Ttas, Cheryl J" sort="Fitzer Ttas, Cheryl J" uniqKey="Fitzer Ttas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name><affiliation wicri:level="1"><mods:affiliation>Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel</mods:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Teva Pharmaceutical Industries Ltd, Petach Tikva</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-03-15">2009-03-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="564">564</biblScope><biblScope unit="page" to="573">573</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">5B1103AD18D631B83CB2914DC8D246159F83891D</idno><idno type="DOI">10.1002/mds.22402</idno><idno type="ArticleID">MDS22402</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MAO‐B inhibitor</term><term>Parkinson's disease</term><term>disease modification</term><term>neuroprotection</term><term>rasagiline</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of this study to compare the long‐term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early‐start group) or placebo for 6 months followed by rasagiline (delayed‐start group) in the TEMPO study. Subjects who chose to participate in an open‐label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5‐year follow‐up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early‐start versus delayed‐start rasagiline group. Although the interaction between treatment and time was significant, values for the early‐start group were better than the delayed‐start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early‐start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD. © 2008 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000327 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000327 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:5B1103AD18D631B83CB2914DC8D246159F83891D
|texte= Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |